Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
May 16, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
May 12, 2022 16:05 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 12, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
May 11, 2022 16:15 ET
|
Athira Pharma, Inc.
Urges Shareholders to Vote TODAY “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
May 09, 2022 07:00 ET
|
Athira Pharma, Inc.
– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
May 05, 2022 12:04 ET
|
Athira Pharma, Inc.
Joins Institutional Shareholder Services in Recommending a Vote on Athira’s WHITE Proxy Card Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph...
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
May 05, 2022 08:00 ET
|
Athira Pharma, Inc.
Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
May 04, 2022 18:46 ET
|
Athira Pharma, Inc.
Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card Today BOTHELL,...
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
April 26, 2022 08:00 ET
|
Athira Pharma, Inc.
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April ...
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
April 20, 2022 09:02 ET
|
Athira Pharma, Inc.
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April 20,...
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
April 05, 2022 16:04 ET
|
Athira Pharma, Inc.
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card Highlights successful...